CDPPB
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


CDPPB
Description :
CDPPB is a selective, orally active mGluR5 allosteric modulator. CDPPB increases AKT and ERK1/2 activation and augments the BDNF mRNA. CDPPB inhibits caspase-3 activation and mitochondrial dysfunction. CDPPB improves cognitive impairment, depression, and Huntington's disease[1][2][3][4][5][6][7][8][9].UNSPSC :
12352005Hazard Statement :
H302, H315, H319, H335Target :
Akt; Caspase; ERK; mGluR; Mitochondrial MetabolismType :
Reference compoundRelated Pathways :
Apoptosis; GPCR/G Protein; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Neuronal Signaling; PI3K/Akt/mTOR; Stem Cell/WntApplications :
Neuroscience-NeuromodulationField of Research :
Neurological DiseaseAssay Protocol :
https://www.medchemexpress.com/cdppb.htmlPurity :
98.01Solubility :
DMSO : 100 mg/mL (ultrasonic)Smiles :
O=C(NC1=CC(C2=CC=CC=C2)=NN1C3=CC=CC=C3)C4=CC=CC(C#N)=C4Molecular Formula :
C23H16N4OMolecular Weight :
364.40Precautions :
H302, H315, H319, H335References & Citations :
[1]Kinney GG, et, al. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther. 2005 Apr; 313 (1) :199-206.|[2]Guan DF, et al. The mGluR5 positive allosteric modulator CDPPB inhibits SO₂-induced protein radical formation and mitochondrial dysfunction through activation of Akt in mouse hippocampal HT22 cells. Cell Mol Neurobiol. 2015 May;35 (4) :573-83. |[3]Chen T, et al. Protective effects of mGluR5 positive modulators against traumatic neuronal injury through PKC-dependent activation of MEK/ERK pathway. Neurochem Res. 2012 May;37 (5) :983-90.|[4]Horio M, et al. Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on phencyclidine-induced cognitive deficits in mice. Fundam Clin Pharmacol. 2013 Oct;27 (5) :483-8.|[5]Płoska A, et al. Neurochemical changes underlying cognitive impairment in olfactory bulbectomized rats and the impact of the mGlu5-positive allosteric modulator CDPPB. Brain Res. 2021 Oct 1;1768:147577.|[6]Doria JG, et al. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease. Neurobiol Dis. 2015 Jan;73:163-73. |[7]Zhang L, et al. Post-stress Social Interaction and 3-Cyano-N- (1,3-Diphenyl-1H-Pyrazol-5-yl) Benzamide Treatment Attenuate Depressive-like Behavior Induced by Repeated Social Defeat Stress. Neuroscience. 2024 Feb 6;538:11-21.|[8]Miller-Rhodes P, et al. Sex-specific behavioral impairments produced by neonatal exposure to MK-801 are partially reversed by adolescent CDPPB treatment. Neurotoxicology and Teratology, 2022, 89: 107053.|[9]Bellozi PMQ, et al. A positive allosteric modulator of mGluR5 promotes neuroprotective effects in mouse models of Alzheimer's disease. Neuropharmacology. 2019 Dec 1;160:107785.Shipping Conditions :
Room TemperatureStorage Conditions :
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category :
Reference compound1Clinical Information :
No Development ReportedIsoform :
MGluR5CAS Number :
[781652-57-1]

